Human Coagulation Factor VII Market

Market Overview

Human coagulation factor VII is an essential blood-clotting protein, also called a hemophilic factor produced in the liver. Human coagulation factor VII is a key factor of the intrinsic clotting encoded by the F8 gene in the humans. The deficiency of human coagulation factor VII can lead to excessive and prolonged bleeding after an injury or surgery, since the blood is unable to clot in this condition.

This deficiency is either inherited or acquired, most common example hemophilia that is inherited medical condition. The global human coagulation factor VII market is expected to grow during the forecast period due to the increasing prevalence of hemophilia, and increasing awareness regarding the disease prevention and treatment especially in the developing countries.

The outbreak of coronavirus has been declared a public health emergency by the World Health Organization, since the disease has spread to almost all countries across the globe. Pandemic coronavirus is believed to have a severe impact on the global human coagulation factor VII market.

Human coagulation factor VII market is being shuttered around the world causing an unusual technology and business model transformation. The outbreak of coronavirus has brought on many aspects, like falling business assurance, uncertainty about future, massive slowing of the supply chain, and others.

The major driver of the global human coagulation factor VII market growth is the increasing cases of hemophilia across the globe. Out of total hemophilia population, 80% population is from developing countries. The government is taking various steps to aware people regarding hemophilia disease, especially in developing countries is likely to drive the market.

The emergence of new procedures for the progress of cost-effective and safer products is another major factor driving the market growth. However, limited awareness about the usage of human coagulation factor VII market among medical professionals and policy makers can restrain the growth of the global human coagulation factor VII market.

Human coagulation factor VII market has been segmented on the basis of product type, application, and end-user.

Based on the product type	Plasma-derived factor VII Recombinant factor VII
Based on the application	Hemophilia Surgery Spontanous / Trauma Others
Based on the end-use	Hospitals Ambulatory Surgery Centers Specialty Clinics Others

Based on the product type, the recombinant factor VII segment is expected to dominate the global human coagulation factor VII market due to the efficiency and safety associated with the use of recombinant products as compared to plasma-derived factor VII. Based on the application, the hemophilia segment is expected to hold a major share in the global human coagulation factor VII market followed by surgery. Based on the end-user, hospitals are expected to be the most profitable segment in the global human coagulation factor VII market.

North America is likely to dominate the global human coagulation factor VII market due to the increasing number of hemophilia patients in the region. Also, increase in healthcare expenditure, and rising awareness about hemophilia in developed countries are likely to drive the global human coagulation factor VII market in the region.

North America is expected to be followed by Europe. Asia-Pacific is expected to grow in the human coagulation factor VII market due to the rising cases of hemophilia. Furthermore, the adoption of various awareness programs by government, and increasing healthcare expenditure in countries like India and China are expected to boost the human coagulation factor VII market in the region.

Some of the market participants in the global human coagulation factor VII market identified across the value chain include: Baxter International Inc., Grifols, S.A., Bayer AG, CSL Limited, Novo Holdings A/S, Pfizer Inc., Octapharma AG, Biogen Inc., Kedrion SpA, Hualan Biological Engineering, Inc., and others.